New quick-turnaround, minimally-invasive liquid biopsy test can be used for dynamic resistance monitoring of T790M and other important hotspot mutations and provides clinically actionable data to support personalized treatment paths.
WESTLAKE VILLAGE – May 16, 2017 – Cynvenio Biosystems, Inc., a leader in personalized medicine technology and cancer diagnostics, has released its ClearID Lung Cancer blood test. Leveraging a highly-sensitive next-generation sequencing panel of 11 genes known to be altered in lung cancer, this new test is designed to quickly and accurately identify tumor-related genetic mutations that can be treated with targeted therapies.
ClearID Lung Cancer uses Cynvenio’s LiquidBiopsy® approach to identify circulating tumor DNA burden and detects somatic mutations as low as 0.13% with an accuracy of 99.76%, and a sensitivity of 95.9%. The test can be used at initial diagnosis to support treatment stratification and identification of targeted therapies. During treatment, it can be used to detect emergent genetic mutations associated with resistance to therapy and identify alternate therapeutic options.
The test results are available within 5-7 days and summarized in a report containing clinical interpretations of the identified biomarkers and variants, their association with drugs, related clinical trials, and experimental therapies to support treatment strategies.
“ClearID Lung Cancer provides physicians and their patients with a customized lung cancer panel that is focused on actionable mutations," said Dr. Paul Y. Song, Cynvenio’s Chief Medical Officer. "With a rapid turnaround time, the test enables quicker response times and more individualized and effective treatment.”
ClearID Lung Cancer can be used to complement conventional tissue biopsy. Requiring only a standard blood draw, ClearID is easier on the patient and can be repeated frequently to monitor changes in tumor status over time. ClearID is particularly useful when there is difficulty obtaining tissue biopsy material, or when it is not practical or advisable to do so for clinical reasons.
About Cynvenio Biosystems, Inc.
Cynvenio’s liquid biopsy testing technology is leading the way to more affordable and clinically actionable precision medicine strategies for cancer patients. Among the company’s breakthroughs is its line of ClearID® tests for greatly improved cancer detection and monitoring via a patient-friendly blood draw, and a suite of proprietary, distributable LiquidBiopsy® platforms and consumables for deployment in hospitals and third party diagnostic labs. Cynvenio is based in Westlake Village, California. For more information, please visit www.cynvenio.com, www.clearidmonitoring.com and www.liquidbiopsy.com.
LiquidBiopsy® and ClearID® are registered trademarks of Cynvenio Biosystems, Inc.